Abstract Purpose of Review Novel non-steroidal mineralocorticoid receptor (MR)
antagonists (MRAs) are a new class of drugs blocking adverse MR-mediated effects with an …

Mineralocorticoid receptor antagonists (MRAs) are key agents in guideline‐oriented drug
therapy for cardiovascular diseases such as chronic heart failure with reduced ejection …

Chronic kidney disease (CKD) in patients with type 2 diabetes (T2D) is a major health
challenge associated with a disproportionately high burden of end‐stage renal disease …

Nonsteroidal mineralocorticoid receptor antagonists (MRAs) are a new class of drugs
developed to address the medical need for effective and safer treatment to protect the kidney …

Abstract Purpose of Review This review focuses on new clinical data involving a novel class
of drugs, nonsteroidal mineralocorticoid receptor antagonists (NS-MRAs), specifically …

Abstract Purpose of Review Type 2 diabetes (T2D) is associated with an increased risk of
diabetic kidney disease (DKD), cardiovascular disease, and heart failure, in part through …

Diabetic kidney disease (DKD) develops in∼ 40% of patients with diabetes and is the most
common cause of chronic kidney disease (CKD) worldwide. Patients with CKD, especially …

Chronic kidney disease (CKD) is one of the most frequent complications associated with
type 2 diabetes mellitus (T2DM) and is also an independent risk factor for cardiovascular …

Despite existing treatments, patients with heart failure and chronic kidney disease (CKD)
remain at high risk for adverse outcomes and progression to end-stage disease. Steroidal …

Abstract Purpose of Review We aim to review the mechanism of action and safety profile of
mineralocorticoid receptor antagonists (MRAs) and discuss the differences between …